Boston Scientific Confirms Common Stock Trading Symbol BSX

TL;DR

**BSX filed an 8-K confirming its common stock trading symbol and par value.**

AI Summary

Boston Scientific Corporation filed an 8-K on January 8, 2024, to disclose that its Common Stock, with a $0.01 par value per share, is registered for trading under the symbol BSX. This filing, under Regulation FD Disclosure, confirms the company's compliance with SEC reporting requirements. This matters to investors because it reaffirms the public trading status of their shares and ensures transparency regarding the company's foundational stock information.

Why It Matters

This filing confirms the basic trading information for Boston Scientific's stock, providing clarity and ensuring regulatory compliance for investors.

Risk Assessment

Risk Level: low — This filing is purely informational, confirming existing stock details and poses no new financial or operational risks.

Analyst Insight

A smart investor would note this filing as a routine compliance update, confirming the stability of basic stock information, but it doesn't warrant immediate action.

Key Numbers

• $0.01 — par value per share (the stated par value for Boston Scientific's Common Stock)

Key Players & Entities

• BOSTON SCIENTIFIC CORPORATION (company) — the registrant filing the 8-K
• $0.01 (dollar_amount) — par value per share of Common Stock
• BSX (company) — trading symbol for Common Stock
• January 8, 2024 (date) — date of earliest event reported and filing date

Forward-Looking Statements

• Boston Scientific will continue to trade under the BSX ticker. (BOSTON SCIENTIFIC CORPORATION) — high confidence, target: N/A

FAQ

From the Filing

0000885725-24-000003.txt : 20240108 0000885725-24-000003.hdr.sgml : 20240108 20240108070636 ACCESSION NUMBER: 0000885725-24-000003 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 24 CONFORMED PERIOD OF REPORT: 20240108 ITEM INFORMATION: Regulation FD Disclosure FILED AS OF DATE: 20240108 DATE AS OF CHANGE: 20240108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BOSTON SCIENTIFIC CORP CENTRAL INDEX KEY: 0000885725 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 042695240 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11083 FILM NUMBER: 24518300 BUSINESS ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 BUSINESS PHONE: 508-683-4000 MAIL ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 8-K 1 bsx-20240108.htm 8-K bsx-20240108 0000885725 false 0000885725 2024-01-08 2024-01-08 0000885725 us-gaap:CommonStockMember 2024-01-08 2024-01-08 0000885725 bsx:SeniorNotedue2027Member 2024-01-08 2024-01-08 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________________________ FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 _____________________________________________________________________ Date of Report (Date of earliest event reported): January 8, 2024 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-11083 04-2695240 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)      300 Boston Scientific Way , Marlborough , Massachusetts                  01752-1234     (Address of principal executive offices)                           (Zip Code) ( 508 ) 683-4000 (Registrant's telephone number, including area code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol Name of each exchange on which registered Common Stock, $0.01 par value per share BSX New York Stock Exchange 0.625% Senior Notes due 2027 BSX27 New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company    ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ☐ Item 7.01 REGULATION FD On January 8, 2024, Boston Scientific Corporation (the “ Company ”) issued a press release (the “ Press Release ”) announcing that the Company and Axonics, Inc. (“ Axonics ”) have executed a definitive agreement pursuant to which the Company agreed to acquire Axonics (the “